Lactam-stapled semaglutide derivatives show enhanced serum and proteolytic stability for GLP-1R targeting
Background
Glucagon-like peptide-1 receptor (GLP-1R) ligands, such as semaglutide, are crucial in treating type 2 diabetes and obesity due to their potent glucose-lowering and weight-reducing effects. However, peptide drugs often face limitations like rapid enzymatic degradation and short half-lives, necessitating frequent administration. Enhancing the stability of these peptides without compromising receptor binding is a key challenge in drug discovery, aiming to improve pharmacokinetics and patient compliance for metabolic disorders.
Study Design
Researchers designed 108 lactam-stapled peptide candidates derived from a short semaglutide GLP-1R-engaging segment using structure-guided modeling and virtual screening. From these, 35 peptides were successfully synthesized and characterized. The primary endpoint was the evaluation of serum and proteolytic stability, comparing the stapled analogues against semaglutide. Molecular dynamics simulations and MM-GBSA analysis were also performed to predict receptor-compatible poses and interaction patterns for representative analogues.
Results
Most of the synthesized lactam-stapled semaglutide analogues exhibited improved serum and proteolytic stability when compared to the parent semaglutide. Specifically, three analogues—11CP-17B, 11CP-17N, and 11CP-19N—demonstrated the most favorable stability profiles among the tested candidates. These enhanced stability characteristics are critical for potential drug development. Molecular dynamics simulations and MM-GBSA analysis provided consistent evidence, predicting that these analogues maintain receptor-compatible poses and favorable interaction patterns with the GLP-1R. This suggests that the stapling strategy successfully conferred stability without compromising the structural integrity required for receptor engagement.
The study identified 11CP-17B, 11CP-17N, and 11CP-19N as having the most favorable stability profiles, significantly outperforming semaglutide in serum and proteolytic resistance.
Key Findings
- 108 lactam-stapled semaglutide-derived peptide candidates were designed via structure-guided modeling.
- 35 stapled peptide analogues were successfully synthesized and characterized.
- Most stapled analogues showed improved serum and proteolytic stability relative to semaglutide.
- Analogues 11CP-17B, 11CP-17N, and 11CP-19N exhibited the most favorable stability profiles.
- Molecular dynamics simulations confirmed receptor-compatible poses and favorable interaction patterns for stable analogues.
Why It Matters
This research defines a practical strategy for constructing highly stabilized semaglutide-derived peptide scaffolds, paving the way for next-generation GLP-1R agonists. Improved stability could translate to longer half-lives, enabling less frequent dosing and enhanced patient convenience for individuals managing type 2 diabetes and obesity. For peptide users and biohackers, this highlights the potential for structural modifications like lactam stapling to overcome pharmacokinetic limitations of current peptides. While still preclinical, these findings provide a strong basis for future functional optimization and in vivo testing, moving closer to more effective and user-friendly therapeutic protocols.
semaglutide
glp-1r
peptide-stability
drug-design
metabolic-disorders
in-vitro